JNJ vs LH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Labcorp (LH) presents a mixed profile with a stable Piotroski F-Score of 4/9 and a current price ($259.57) positioned between its defensive Graham Number ($157.1) and growth-based intrinsic value ($308.57). While the company demonstrates strong earnings growth (15.7% YoY) and a highly attractive forward P/E of 13.46, these fundamentals are countered by a bearish technical trend and significant insider selling. The long-term earnings track record is exceptional, but the lack of immediate momentum and mediocre health score suggest a neutral short-term outlook.
Compare Another Pair
Related Comparisons
JNJ vs LH: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Labcorp Holdings Inc. (LH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.